Beijing-based biopharma Staidson its trialling its anti-C5a monoclonal antibody drug, BDB-001, in severe Covid-19 in collaboration of Spanish CRO Pivotal.
The European study will enrol 60 severe Covid-19 patients who will randomised to receive either BDB-001 or placebo and best supportive care.
Evidence has suggested that C5a is a powerful inflammatory mediator and antibodies acting against C5a could therefore reduce the pulmonary dysfunction, which has characterised Covid-19.
Staidson senior vice-president Dr. Lixin Jiang said: “As one of our products in our pipeline, BDB-001 has been tested in over 69 healthy volunteers and Covid-19 patients in five clinical trials running in China.
“The promising therapeutic results in severe COVID-19 after BDB-001 compassionate administration has already been accepted for publication by top peer-reviewed journals.
“We are extremely happy to collaborate with the Pivotal team for clinical trial application in Europe, who have efficiently obtained final approval in less than six weeks and have begun activating sites to enrol patients.”
